المؤلفون: Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Igino Simonetti, Carmine Picone, Ester Simeone, Lucia Festino, Vito Vanella, Maria Grazia Vitale, Agnese Montanino, Alessandro Morabito, Francesco Izzo, Paolo Antonio Ascierto, Antonella Petrillo

المصدر: Diagnostics; Volume 13; Issue 2; Pages: 302

مصطلحات موضوعية: immunotherapy, radiological response assessment, Recist 1.1, i-Recist, immuno-related adverse events

الوصف: Immunotherapy denotes an exemplar change in an oncological setting. Despite the effective application of these treatments across a broad range of tumors, only a minority of patients have beneficial effects. The efficacy of immunotherapy is affected by several factors, including human immunity, which is strongly correlated to genetic features, such as intra-tumor heterogeneity. Classic imaging assessment, based on computed tomography (CT) or magnetic resonance imaging (MRI), which is useful for conventional treatments, has a limited role in immunotherapy. The reason is due to different patterns of response and/or progression during this kind of treatment which differs from those seen during other treatments, such as the possibility to assess the wide spectrum of immunotherapy-correlated toxic effects (ir-AEs) as soon as possible. In addition, considering the unusual response patterns, the limits of conventional response criteria and the necessity of using related immune-response criteria are clear. Radiomics analysis is a recent field of great interest in a radiological setting and recently it has grown the idea that we could identify patients who will be fit for this treatment or who will develop ir-AEs.

وصف الملف: application/pdf

العلاقة: Medical Imaging and Theranostics; https://dx.doi.org/10.3390/diagnostics13020302Test

الإتاحة: https://doi.org/10.3390/diagnostics13020302Test

المؤلفون: Atsushi Miyauchi, Hiroaki Ito, Masahiro Komori, Masamitsu Hyodo, Shu-ichi Matsumoto, 伊藤 広明, 兵頭 政光, 宮内 敦史, 小森 正博, 松本 宗一

المصدر: 頭頸部外科 / JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY. 2023, 33(2):219

المؤلفون: Martin Schlumberger, Francesca Sessa, Valentina Damiano, Tommaso Porcelli, C. Gambale, Domenico Salvatore, Michele Klain, E. Matano, Cristina Luongo, R. Morra

المساهمون: Luongo, C, Morra, R, Gambale, C, Porcelli, T, Sessa, F, Matano, E, Damiano, V, Klain, M, Schlumberger, M, Salvatore, D

المصدر: Journal of Endocrinological Investigation

مصطلحات موضوعية: Male, endocrine system diseases, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Thyrotropin, Kaplan-Meier Estimate, Thyroid immuno-related adverse events, Thyroid Function Tests, Gastroenterology, Endocrinology, Antineoplastic Agents, Immunological, Retrospective Studie, Risk Factors, Neoplasms, Medicine, Euthyroid, Immune Checkpoint Inhibitors, Thyrotoxicosi, Anti-thyroid antibodie, Aged, 80 and over, biology, Thyroid, Middle Aged, Anti-thyroid autoantibodies, Progression-Free Survival, medicine.anatomical_structure, Anti-thyroid antibodies, Thyrotoxicosis, Treatment Outcome, Original Article, Female, Survival Analysi, Immunotherapy, Antibody, Thyroid function, hormones, hormone substitutes, and hormone antagonists, Human, Adult, medicine.medical_specialty, endocrine system, Immune Checkpoint Inhibitor, Hypothyroidism, Internal medicine, Endocrine system, Humans, Adverse effect, Aged, Retrospective Studies, Thyroid immuno-related adverse event, business.industry, Risk Factor, Survival Analysis, Thyroid Function Test, biology.protein, Neoplasm, business

الوصف: Background and purposeImmune checkpoint inhibitors (ICIs) are monoclonal antibodies that enhance the immune response against cancer cells. ICIs are generally well tolerated, although endocrine immune-related adverse events (irAEs) are common. We investigated the risk factors for thyroid irAEs in patients treated with ICIs. Moreover, we evaluated the clinical outcome of subjects who became hypothyroid compared to euthyroid patients.Patients and methodsWe retrospectively analyzed a series of 195 consecutively subjects treated with ICIs for metastatic tumors at the University of Naples “Federico II” between January 2014 and March 2020. Only subjects tested for thyroid function before and during the treatment with ICIs were included.ResultsIn the 96 patients treated with ICIs who were included [66 males, median age: 62 years (27–87)], thyroid irAEs occurred in 36 (37.5%), 16 (16.7%) a transient thyrotoxicosis, and 20 (20.8%) an hypothyroidism (in nine subjects hypothyroidism was preceded by a transient thyrotoxicosis). Only baseline TSH levels above 1.67 mIU/L and positive anti-thyroid antibodies (Ab-T) were associated with a higher risk of hypothyroidism. Patients with hypothyroidism during ICI treatment showed an improved 2-year PFS (HR = 0.82 CI 0.47–1.43;p = 0.0132) and OS (HR = 0.38 CI 95% 0.17–0.80;p = 0.011) compared to euthyroid patients.ConclusionsBaseline TSH levels above 1.67 mIU/L and presence of Ab-T are risk factors for the development of thyroid irAEs. Patients affected by thyroid irAEs showed a longer survival than patients who remained euthyroid.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f70cab2a3295a14ad0932827ac19a397Test
http://europepmc.org/articles/PMC8357750Test

المؤلفون: Naoko OKIYAMA, Ryota TANAKA, 沖山 奈緒子, 田中 亮多

المصدر: 日本臨床免疫学会会誌 / Japanese Journal of Clinical Immunology. 2017, 40(2):95

المؤلفون: Giovanni Luca Ceresoli, Barbara Melotti, Diego Signorelli, Francesco Verderame, Alice Lunghi, Vieri Scotti, Enrico Cortesi, Giacomo Cartenì, Daniele Turci, Gianpiero Fasola, Enrico Ricevuto, Paolo Marchetti, Carmelo Tibaldi, Alfonso Illiano, Luisa Fioretto, Diana Giannarelli, Editta Baldini, Antonio Frassoldati, Carmine Pinto, Biagio Ricciuti, Giampiero Romano, Valeria Stati

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Outcomes, NO, Efficacy, 03 medical and health sciences, 0302 clinical medicine, Immuno-Related adverse events, Immunopathology, Internal medicine, medicine, Nivolumab, Progression-free survival, Lung cancer, Adverse effect, business.industry, Retrospective cohort study, medicine.disease, 030104 developmental biology, 030220 oncology & carcinogenesis, Expanded access, business

الوصف: Objectives The incidence of any and of severe-grade immune-related adverse events (irAEs) with second-line nivolumab monotherapy is 31–65 % and 2–5 % respectively. While potentially serious and even fatal, in the absence of an appropriate therapy, such events might be indicators of the activation of the immune system and, potentially, of efficacy. Materials and Methods We collected the records of 1959 non-small-cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access program, and we registered the appearance of any and of severe grade irAEs. We retrospectively searched for correlations between toxicity and efficacy parameters by using Cox's regression analysis. Results Overall, 342 (17.8%) patients developed an irAE of any grade. We observed that patients developing irAE of any grade achieved a significantly higher response rate (RR 27.2% vs 15.2%; p Conclusions This report, performed in Caucasian NSCLC patients, showed that the appearance of irAEs correlated with outcome.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a28894fc3abc7f2350fa495f0a094b05Test
http://hdl.handle.net/11392/2418755Test